With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
Experts call for integrated, evidence-based approaches to tackle rising dengue, malaria, and chikungunya burden in Indian cities
As part of the partnership, Boehringer Ingelheim will provide access to its opnMe® platform, enabling broader scientific exchange and driving innovation-led research.
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Dr Shivkumar Kalyanaraman emphasizes need for quality research, partnerships, and measurable outcomes
Experts highlighted that robust pharmacopoeial frameworks are essential for maintaining the quality, safety and efficacy of medicines
The grant backed by Novartis to strengthen academia-industry collaboration across all seven NIPERs
The ninth edition of the event brought together over 800 delegates, more than 60 national and international speakers, and 20+ partner organisations across 10 sessions
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
